Nano-crystalline megestrol acetate

Phase 3Small molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

Nano-crystalline megestrol acetate is one of 241 small molecule programs targeting Cachexia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

240

Competitors

Pipeline

Status by Indication[3][1]

Indication

CachexiaNot yet recruiting

Lung CancerNot yet recruiting

Non-Small Cell Lung CancerRecruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaNot yet recruiting

Small Cell Lung CancerNot yet recruiting

CachexiaPhase 3

Not yet recruiting

Lung CancerPhase 2

Not yet recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Colorectal CancerPreclinical

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Not yet recruiting

Small Cell Lung CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

32 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

9 3

Nano-crystalline megestrol acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 4

Divarasib

Roche

Phase 3

7 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Cachexia

NCT06940102

Q2 2027

Phase 3Not yet recruiting

Small Cell Lung Cancer

NCT06961201

Q4 2027

Phase 2Not yet recruiting

Lung Cancer

NCT07092137

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT07150663

Phase 3Not yet recruiting

Head and Neck Squamous Cell Carcinoma

NCT06772428

Phase 3Not yet recruiting

Cachexia

NCT06961188

Clinical

Trials by Indication[1]

Cachexia2 trials

Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.··NCT06940102·120 enrolled

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT06961188·174 enrolled

Non-Small Cell Lung Cancer1 trial

Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT07150663·134 enrolled

Lung Cancer1 trial

Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer

Not yet recruiting·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT07092137·116 enrolled

Small Cell Lung Cancer1 trial

Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT06961201·94 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT06772428·96 enrolled

2 more indications

Colorectal Cancer1 trial

Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·N/A·NCT06830018·76 enrolled

Advanced Pancreatic Ductal Adenocarcinoma1 trial

Efficacy and Safety of Nano-Megestrol Acetate in the Treatment of Anorexia-Cachexia Syndrome in Patients With Advanced Pancreatic Cancer: A Randomized, Controlled, Prospective Study

Recruiting·SShandong Cancer Hospital and Institute·Preclinical·NCT07408505·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Nano-crystalline megestrol acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nano-crystalline megestrol acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nano-crystalline megestrol acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

Nano-crystalline megestrol acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Cachexia2 trials

Non-Small Cell Lung Cancer1 trial

Lung Cancer1 trial

Small Cell Lung Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Colorectal Cancer1 trial

Advanced Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News